1. Scrip
  2. >>R&D

Early Stage Science Watch

 
• By Alexandra Shimmings

Scrip scans for early stage research – from bench to clinic – that could lead to novel treatments or changes in therapy recently published in major science journals.

Malaria
Malaria Infection • Source: Shutterstock

Malaria is giving up its genomic secrets as new research reveals that a larger proportion of its genes are essential than in any organism so far studied. The findings by researchers at the Wellcome Trust Sanger Institute and GlaxoSmithKline PLC and published in Cell (July 13), deepen the knowledge of malaria biology, and should help speed up the understanding of gene function to aid in drug and vaccine development.

Using a new "DNA Barcoding" method developed at the Sanger Institute, the team showed that the malaria parasite can easily...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from R&D

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 
• By Alaric DeArment

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from Scrip

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By Manas Mishra

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.